TABLE 4.
Comparison of Absorbed Dose Coefficients and Absorbed Doses for Several Prostate-Specific Compounds
| Target organ | Unit | 124I-PSMA |
123I-MIP- 1072 |
123I-MIP- 1095 |
Pentixafor | DOTATOC | DOTATATE | 18F-FDG | PSMA-IT |
|---|---|---|---|---|---|---|---|---|---|
| Zechmann (33) |
Barrett (36) |
Barrett (36) |
Herrmann (25) |
Sandstrom (34) |
Sandstrom (34) |
ICRP 106 (35) |
This work | ||
| Kidneys | mSv/ MBq |
1.39E100 | 5.4E–02 | 1.10E–2 | 3.50E–02 | 8.20E–02 | 9.30E–02 | 1.70E–02 | 2.20E–01 |
| Liver | mSv/ MBq |
1.66E–00 | 2.4E–02 | 5.8E–2 | 1.75E–02 | 4.10E–02 | 5.00E–02 | 2.10E–02 | 4.31E–02 |
| Spleen | mSv/ MBq |
7.7E–01 | 2.3E–2 | 4.7E–2 | 5.38E–02 | 1.08E–01 | 1.09E–01 | 1.10E–02 | 6.34E–02 |
| Urinary bladder wall | mSv/ MBq |
5.7E–01 | 9.2E–2 | 2.1E–2 | 8.14E–02 | 1.19E–01 | 9.80E–02 | 1.30E–01 | 6.74E–02 |
| Effective dose coefficient |
mSv/ MBq |
5.8E–01 | 2.5E–2 | 3.2E–2 | 1.56E–02 | 2.10E–02 | 2.10E–02 | 1.90E–02 | 1.99E–02 |
| Typical injected activity |
MBq | 67 | 370 | 370 | 150 | 185 | 150 | 370 | 150 |
| Effective dose | mSv | 38.9 | 9.3 | 11.8 | 2.3 | 3.9 | 3.2 | 7.0 | 3.0 |